Who are Human Dopaminergic Progenitor Cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, IL-7/IL-15 pre-treated CD19 cells, ACP, Cellular Matrix / A-CP-HA Kit, PCRA (Intermittent injection), Cord blood.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-dopaminergic-progenitor-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Human Dopaminergic Progenitor Cells — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Dopaminergic Progenitor Cells (Human Dopaminergic Progenitor Cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Neurology.

phase 2 Cell therapy Neurology Biologic Live · refreshed every 30 min

Target snapshot

Human Dopaminergic Progenitor Cells (Human Dopaminergic Progenitor Cells) — iRegene Therapeutics Co., Ltd.. Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human Dopaminergic Progenitor Cells TARGET	Human Dopaminergic Progenitor Cells	iRegene Therapeutics Co., Ltd.	phase 2	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human Dopaminergic Progenitor Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/human-dopaminergic-progenitor-cells. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab